Revolution Medicines vs Amgen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Revolution Medicines Inc (RVMD)

Q3 202627 Jun – 16 Sep 2026

▲3▼1

FDA approval turns Revolution Medicines into commercial-stage company

Daraxonrasib Phase 3 survival win Strong Phase 3 data for daraxonrasib in metastatic pancreatic cancer nearly doubled median overall survival, a major clinical win that supports a roughly $40 billion valuation and validates the company's RAS-targeted approach.
This was the key clinical catalyst that re-rated the stock during the quarter.
FDA approval of Rasonque In September the FDA approved daraxonrasib (Rasonque), the first RAS-targeted pancreatic cancer drug, making Revolution Medicines a commercial-stage company with real revenue potential and a first-mover position.
The approval is the single biggest new event, changing the company's business model.
Regulatory designations and funding Breakthrough Therapy and Orphan Drug designations, EMA accelerated review, and a Royalty Pharma deal fund the pipeline without dilution, while Parnassus Growth Equity initiated a position, signaling institutional confidence.
These developments de-risk the launch and strengthen the balance sheet without shareholder dilution.
Cost and pricing concerns A wider-than-expected Q2 loss and raised 2026 spending guidance (second time) cast doubt on profitability timing, while Rasonque's $39,800 monthly price raises insurer coverage and patient affordability concerns that could limit sales.
This is the main counterweight, showing the commercial path is not without financial and access risks.

September 202626 Aug – 16 Sep 2026

▲3

FDA approval turns Revolution Medicines into a commercial cancer drugmaker

FDA approves first RAS-targeted pancreatic cancer drug The FDA approved daraxonrasib, sold as Rasonque, for previously treated metastatic pancreatic cancer. It is the first targeted pill for this hard-to-treat disease, nearly doubling median survival versus chemotherapy. This turns a clinical-stage company into one with an approved product and real revenue potential, lifting the stock.
This is the single biggest new event of the period and the core reason RVMD is moving.
Price set at $39,800 per month Revolution priced Rasonque at $39,800 for a 30-day supply, about $477,600 a year before discounts. That is high enough to raise concerns about whether insurers will cover it and whether patients can afford it, which could limit sales even though the price itself supports revenue per patient.
Pricing is the main commercial counterweight to the approval and directly affects how much revenue the drug can generate.
Royalty Pharma deal funds pipeline without dilution A new partnership with Royalty Pharma provides funding for Revolution's pipeline without selling more shares. That matters because the company had no revenue in FY2025 and lost about $1.1 billion, so this eases the need for cash and protects existing shareholders from dilution.
It answers how the company pays for its pipeline now that it has a product but still spends heavily.
Fund manager cites drug as potential new standard of care Parnassus Growth Equity Fund added Revolution Medicines as a new holding, saying daraxonrasib's late-stage results suggest it could become a standard treatment for pancreatic cancer with significant commercial potential. A respected fund buying in signals growing institutional confidence, which can support the stock.
It shows professional investors are treating the approval as a durable long-term opportunity, not just a one-day event.

Latest26 Aug – 16 Sep 2026

▲3

FDA approval turns Revolution Medicines into a commercial cancer drugmaker

FDA approves first RAS-targeted pancreatic cancer drug The FDA approved daraxonrasib, sold as Rasonque, for previously treated metastatic pancreatic cancer. It is the first targeted pill for this hard-to-treat disease, nearly doubling median survival versus chemotherapy. This turns a clinical-stage company into one with an approved product and real revenue potential, lifting the stock.
This is the single biggest new event of the period and the core reason RVMD is moving.
Price set at $39,800 per month Revolution priced Rasonque at $39,800 for a 30-day supply, about $477,600 a year before discounts. That is high enough to raise concerns about whether insurers will cover it and whether patients can afford it, which could limit sales even though the price itself supports revenue per patient.
Pricing is the main commercial counterweight to the approval and directly affects how much revenue the drug can generate.
Royalty Pharma deal funds pipeline without dilution A new partnership with Royalty Pharma provides funding for Revolution's pipeline without selling more shares. That matters because the company had no revenue in FY2025 and lost about $1.1 billion, so this eases the need for cash and protects existing shareholders from dilution.
It answers how the company pays for its pipeline now that it has a product but still spends heavily.
Fund manager cites drug as potential new standard of care Parnassus Growth Equity Fund added Revolution Medicines as a new holding, saying daraxonrasib's late-stage results suggest it could become a standard treatment for pancreatic cancer with significant commercial potential. A respected fund buying in signals growing institutional confidence, which can support the stock.
It shows professional investors are treating the approval as a durable long-term opportunity, not just a one-day event.

July 202627 Jun – 6 Aug 2026

▲3▼1

RVMD Soars on Strong Phase 3 Data, Regulatory Wins, and Competitive Edge

Daraxonrasib Phase 3 Data Revolution Medicines reported strong Phase 3 results for daraxonrasib in metastatic pancreatic cancer, with median overall survival nearly doubling to 13.2 months from 6.7 months, supporting a ~$40B valuation and a $10B+ market opportunity.
This is the primary positive catalyst that drove the stock's surge during the period.
Regulatory Designations and NDA Acceptance The company received Breakthrough Therapy and Orphan Drug designations, EMA accelerated review, and FDA acceptance of the daraxonrasib NDA with a fast-review voucher, building regulatory momentum.
These regulatory milestones accelerate the path to market and boost investor confidence.
Competitor Erasca Legal Woes Erasca faces securities litigation and investigations over alleged misleading comparisons to RVMD's RMC-6236, erasing $2.8B in market cap, which strengthens RVMD's competitive position.
This weakens a rival and reinforces RVMD's leadership in the RAS cancer space.
Wider Q2 Loss and Raised Spending Guidance RVMD reported a wider-than-expected Q2 loss and raised 2026 spending guidance for the second time, raising doubts about how soon the company can reach profitability.
This is a counterweight that could pressure the stock despite positive pipeline news.

23 Jul – 6 Aug 2026

▲3▼1

FDA accepts daraxonrasib NDA, but rising costs test RVMD's valuation

FDA accepts daraxonrasib NDA The FDA accepted Revolution Medicines' application for daraxonrasib in metastatic pancreatic cancer, a key step toward approval. The drug also got a fast-review voucher. This raises the chance of a launch and future sales, supporting the stock.
This is the period's biggest new regulatory event and directly drives RVMD's potential revenue.
Druckenmiller's fund buys RVMD shares Billionaire Stanley Druckenmiller's family office bought 316,000 shares. A well-known investor buying in can boost confidence and attract other buyers, pushing the stock up. It also highlights the drug's strong survival data.
This is a new, specific event that can influence investor sentiment and demand for the stock.
Wider Q2 loss and higher expense guidance Revolution Medicines reported a bigger quarterly loss than expected and raised its 2026 spending forecast for the second time. Costs are climbing fast as it prepares for launch. This raises doubts about how soon it can become profitable, weighing on the stock.
This is the main new negative financial update and a real counterweight to the positive news.
Erasca legal probe continues Hagens Berman is investigating Erasca over alleged misleading claims about its drug, including flawed comparisons to RVMD's RMC-6236. This keeps pressure on a competitor and reinforces RVMD's competitive edge in RAS cancer drugs.
It is a new development in a competitive threat that benefits RVMD's relative position.

27 Jun – 17 Jul 2026

▲4

Revolution Medicines' cancer data and regulatory wins drive RVMD higher

Daraxonrasib Phase 3 survival data and $40B valuation Daraxonrasib nearly doubled median overall survival (13.2 vs 6.7 months) in previously treated metastatic pancreatic cancer, supporting a potential $10B+ opportunity and a ~$40B market value. This validates the pipeline and raises expectations for future revenue.
This is the core clinical catalyst that justifies RVMD's valuation and future revenue potential.
Zoldonrasib combination shows high response rates Phase 1/2 data for zoldonrasib plus chemo in RAS G12D pancreatic cancer showed 82% and 61% response rates in untreated patients, and 50% in previously treated patients. These results support ongoing Phase 3 trials and expand the pipeline's potential.
New positive data for a second drug candidate broadens the growth story and de-risks the pipeline.
Regulatory progress: Breakthrough Therapy, Orphan Drug, EMA accelerated review Daraxonrasib received Breakthrough Therapy and Orphan Drug designations, and the European Medicines Agency launched an accelerated review. The company is nearing completion of its New Drug Application to the FDA, setting the stage for a potential global launch.
Regulatory milestones shorten the path to market and increase the probability of approval, directly impacting future sales.
Erasca legal troubles weaken a competitor Erasca faces a securities class action over alleged improper comparisons to RVMD's RMC-6236 and a patient death, erasing $2.8B in market cap. This strengthens RVMD's competitive position and intellectual property standing in the RAS cancer space.
A weakened competitor reduces competitive pressure and reinforces RVMD's leadership, supporting its pricing power and market share.

Q2 202618 Jun – 26 Jun 2026

▲3

Revolution Medicines advances pancreatic cancer pipeline as rival Erasca faces legal fallout

Phase 3 trial launch for zoldonrasib Revolution Medicines began treating patients in RASolute 305, a Phase 3 trial of zoldonrasib plus chemotherapy for first-line metastatic pancreatic cancer. This is a key step toward a potential new drug, boosting investor confidence in the company's pipeline and future revenue.
This is a major clinical milestone that directly advances RVMD's lead drug and could drive long-term value.
Upcoming data presentations at ESMO GI 2026 Revolution Medicines will present clinical data from its RAS(ON) inhibitor pipeline at the ESMO GI 2026 congress, including oral reports on zoldonrasib combinations and updates on two Phase 3 trials. Positive data could further validate the pipeline and attract investor interest.
Upcoming data readouts are near-term catalysts that can influence RVMD's stock price.
Competitive edge from Erasca patent dispute Revolution Medicines accused rival Erasca of patent infringement and trade secret misappropriation over ERAS-0015, leading to a securities class action against Erasca. This weakens a competitor and reinforces RVMD's intellectual property position in the RAS cancer space.
The legal challenge against Erasca strengthens RVMD's competitive standing and removes a potential rival.

June 202618 Jun – 26 Jun 2026

▲3

Revolution Medicines advances pancreatic cancer pipeline as rival Erasca faces legal fallout

Phase 3 trial launch for zoldonrasib Revolution Medicines began treating patients in RASolute 305, a Phase 3 trial of zoldonrasib plus chemotherapy for first-line metastatic pancreatic cancer. This is a key step toward a potential new drug, boosting investor confidence in the company's pipeline and future revenue.
This is a major clinical milestone that directly advances RVMD's lead drug and could drive long-term value.
Upcoming data presentations at ESMO GI 2026 Revolution Medicines will present clinical data from its RAS(ON) inhibitor pipeline at the ESMO GI 2026 congress, including oral reports on zoldonrasib combinations and updates on two Phase 3 trials. Positive data could further validate the pipeline and attract investor interest.
Upcoming data readouts are near-term catalysts that can influence RVMD's stock price.
Competitive edge from Erasca patent dispute Revolution Medicines accused rival Erasca of patent infringement and trade secret misappropriation over ERAS-0015, leading to a securities class action against Erasca. This weakens a competitor and reinforces RVMD's intellectual property position in the RAS cancer space.
The legal challenge against Erasca strengthens RVMD's competitive standing and removes a potential rival.

18 Jun – 26 Jun 2026

▲3

Revolution Medicines advances pancreatic cancer pipeline as rival Erasca faces legal fallout

Phase 3 trial launch for zoldonrasib Revolution Medicines began treating patients in RASolute 305, a Phase 3 trial of zoldonrasib plus chemotherapy for first-line metastatic pancreatic cancer. This is a key step toward a potential new drug, boosting investor confidence in the company's pipeline and future revenue.
This is a major clinical milestone that directly advances RVMD's lead drug and could drive long-term value.
Upcoming data presentations at ESMO GI 2026 Revolution Medicines will present clinical data from its RAS(ON) inhibitor pipeline at the ESMO GI 2026 congress, including oral reports on zoldonrasib combinations and updates on two Phase 3 trials. Positive data could further validate the pipeline and attract investor interest.
Upcoming data readouts are near-term catalysts that can influence RVMD's stock price.
Competitive edge from Erasca patent dispute Revolution Medicines accused rival Erasca of patent infringement and trade secret misappropriation over ERAS-0015, leading to a securities class action against Erasca. This weakens a competitor and reinforces RVMD's intellectual property position in the RAS cancer space.
The legal challenge against Erasca strengthens RVMD's competitive standing and removes a potential rival.

Amgen Inc (AMGN)

Q3 20268 Jul – 14 Sep 2026

▲2▼2

Amgen Q3: Pelacarsen Blow Sinks Shares, Recalls and Rival Threats Weigh

Pelacarsen failure casts doubt on Amgen's olpasiran Novartis' heart drug pelacarsen failed, and because Amgen's similar olpasiran works the same way, investors feared it could fail too. Shares fell about 10% and BMO downgraded the stock.
This was the single most severe event of the quarter, directly sinking the share price.
Court blocks Colorado's 70% Enbrel price cap A court blocked Colorado's 70% price cap on Enbrel, reducing regulatory risk for Amgen's biggest drug. This removes a threat that could have slashed revenue from a key product.
A major legal win that eased a key overhang on the stock.
Q2 beat and raised guidance, key products grow 26% Amgen's Q2 earnings and revenue beat estimates, and the company raised its full-year guidance. Six key products grew 26%, showing the new drug lineup is driving growth.
Strong financial results and raised outlook support the stock.
Recalls, competition, pipeline setback, cyberattack Corlanor and Sensipar recalls raised quality concerns. Merck's cheaper oral PCSK9 threatens Repatha, Sotyktu may erode Otezla, AMG 513 was discontinued, and a cyberattack triggered lawsuits.
Multiple negative events that weighed on sentiment and future growth prospects.

September 20267 Sep – 14 Sep 2026

▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.
This is the main new force driving AMGN down this period.
BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.
Analyst downgrade is a direct new negative catalyst for the stock.
IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.
A major positive pipeline win that offsets some of the Lp(a) pessimism.
FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.
Regulatory win that improves commercial practicality of a growth drug.

Latest7 Sep – 14 Sep 2026

▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.
This is the main new force driving AMGN down this period.
BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.
Analyst downgrade is a direct new negative catalyst for the stock.
IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.
A major positive pipeline win that offsets some of the Lp(a) pessimism.
FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.
Regulatory win that improves commercial practicality of a growth drug.

August 202629 Jul – 3 Sep 2026

▲2▼2

Amgen beats Q2, raises guidance, but obesity setback and cyberattack weigh

Q2 earnings beat and guidance raise Amgen reported Q2 adjusted EPS of $6.29 and revenue of $10.05B, beating estimates, and raised its 2026 guidance. Six key growth products grew 26%, reducing reliance on older drugs.
This is a new positive fundamental development that directly supports the stock.
Repatha and Tezspire clinical wins Repatha cut death risk by 20% in a major heart trial, and Tezspire met all goals in an eosinophilic esophagitis study. These results lifted shares to a 52-week high and prompted analyst target hikes.
New clinical data and analyst reactions are key drivers of the stock's move this period.
Obesity drug AMG 513 discontinued Amgen discontinued its obesity drug AMG 513, leaving MariTide trailing Eli Lilly and Novo Nordisk in the lucrative obesity market. This raises concerns about Amgen's competitive position.
This is a new negative event that affects future growth prospects.
Cyberattack and drug-price pressure A July cyberattack exposed patient and proprietary data, triggering a class action investigation. Also, a looming US drug-price agreement with mid-sized biotechs could pressure Medicaid revenue.
These are new risk factors that emerged during the period and could weigh on the stock.

8 Aug – 3 Sep 2026

▲3▼1

Amgen Hits 52-Week High on Q2 Beat, Repatha and Tezspire Wins

Repatha Cuts Death Risk 20% in Major Heart Trial Amgen's Repatha reduced death risk by 20% in high-risk heart patients in the VESALIUS-CV trial, a major win for its biggest growth drug. This strengthens the case for wider use and future sales, supporting a higher stock price.
This is a new, high-impact clinical win that directly boosts confidence in Amgen's key growth driver.
Tezspire Meets All Goals in Eosinophilic Esophagitis Trial Amgen and AstraZeneca's Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, a chronic throat condition with few good treatments. This opens a new market and adds to Tezspire's growth story, lifting investor optimism.
New positive trial results expand a key product's potential, a fresh catalyst for the stock.
US Drug Price Agreement with Mid-Sized Biotechs Looms The Trump administration is expected to announce a drug price agreement with mid-sized biotech firms, and Amgen was among companies urged to cut US prices. If Amgen is included, lower Medicaid prices could pressure revenue and weigh on the stock.
This is a new regulatory risk that could directly affect Amgen's pricing and profits.
Analyst Fair Value and Price Targets Raised After Q2 Beat Following Amgen's strong Q2 results, analysts raised their fair value estimate to about $372 and several price targets into the $450 range, citing broad franchise strength. Higher targets can pull the stock up as investors adjust expectations.
This is a new analyst reaction that reflects upgraded expectations and can influence the stock price.

29 Jul – 6 Aug 2026

▲2▼2

Amgen Q2 Beat and Guidance Raise Outweigh Data Breach and Obesity Setback

Q2 earnings beat and raised 2026 guidance Amgen reported Q2 adjusted EPS of $6.29, well above the $5.62 consensus, and revenue of $10.05 billion, up 10% and ahead of forecasts. Management raised full-year revenue and EPS guidance, signaling confidence in the business. This directly boosts the stock as investors see stronger profits ahead.
This is the main new positive event that drove the stock up over 5% this period.
Key growth drivers show strong momentum Six key products, including Repatha, Evenity, Uplizna, and Imdelltra, grew 26% year-over-year and now make up nearly 70% of product sales. This reduces reliance on older drugs like Enbrel and Otezla, which are facing competition. The shift supports future revenue growth and lifts investor confidence.
It explains the underlying strength behind the earnings beat and why the stock rose.
Cybersecurity breach and class action investigation Amgen disclosed a July cyberattack where sensitive patient and proprietary data was stolen. A law firm has launched a class action investigation. This creates legal and reputational risk, which could weigh on the stock, though Amgen says operations are not materially affected.
It is a new negative event that could pressure the stock and is important for a balanced view.
Obesity drug AMG 513 discontinued; MariTide faces tough competition Amgen ended development of early-stage obesity drug AMG 513, leaving MariTide as its only obesity candidate. MariTide's weight-loss data trails Eli Lilly's and Novo Nordisk's drugs, and switching patients may be hard. This raises doubts about Amgen's ability to compete in the lucrative obesity market.
It is a new setback that could limit future growth and is a key counterweight to the positive earnings.

July 20268 Jul – 23 Jul 2026

▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.
This is a major new legal win that directly supports Amgen's revenue outlook.
Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.
New recalls create fresh regulatory and reputational risk that can hurt the stock.
New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.
A new lower-priced competitor directly challenges a key Amgen growth drug.
Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.
New competitive data shows a direct threat to an existing Amgen product.

8 Jul – 23 Jul 2026

▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.
This is a major new legal win that directly supports Amgen's revenue outlook.
Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.
New recalls create fresh regulatory and reputational risk that can hurt the stock.
New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.
A new lower-priced competitor directly challenges a key Amgen growth drug.
Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.
New competitive data shows a direct threat to an existing Amgen product.

Q2 202618 Jun – 3 Jul 2026

▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.
This is the core positive force behind Amgen's business momentum.
MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.
Pipeline progress is a key driver of long-term growth and investor optimism.
Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.
This is a major negative regulatory event that threatens a marketed drug and investor confidence.
Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.
These are new competitive and legal threats that could weigh on Amgen's stock.

June 202618 Jun – 3 Jul 2026

▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.
This is the core positive force behind Amgen's business momentum.
MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.
Pipeline progress is a key driver of long-term growth and investor optimism.
Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.
This is a major negative regulatory event that threatens a marketed drug and investor confidence.
Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.
These are new competitive and legal threats that could weigh on Amgen's stock.

18 Jun – 3 Jul 2026

▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.
This is the core positive force behind Amgen's business momentum.
MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.
Pipeline progress is a key driver of long-term growth and investor optimism.
Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.
This is a major negative regulatory event that threatens a marketed drug and investor confidence.
Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.
These are new competitive and legal threats that could weigh on Amgen's stock.